SPRO: Definitely no congratz on a great quarter!
4 months ago
BiotechBonanza
"SPRO: Suffered setbacks with Tebipenem - net royalty 0% on first $750M sales, milestone reduced from $150M to $101M. Pro forma cash ~$55M to last into 2028. CEO sees Tebipenem as main value driver, decision on IV720 by mid-2026. Risk-reward looks decent at low $2s with ~$2.40 mid-case fair value."
Sentiment
bullish
Conviction
Medium
Tier
Trade Call
Related Stocks
Episode Information
Episode:
SPRO: Definitely no congratz on a great quarter!
Source:
BiotechBonanza
Published:
August 13, 2025
Idea Type:
Stock Idea